Biomax Informatics AG announces that their longtime client, Boehringer Ingelheim, has signed a multi-year license for the BioXM™ Knowledge Management Environment to support their global target discovery research. In addition, the company has extended their license for Biomax’s BioRS™ Integration and Retrieval System.
Boehringer Ingelheim is using the BioXM™ Knowledge Management Environment to build and maintain a target discovery knowledge platform that supports the company’s research on a global scale. The BioXM platform leverages Boehringer Ingelheim’s existing BioRS infrastructure to semantically integrate information from the company’s in-house systems and other proprietary and public data sources including pathways, compounds, sequences, genotypes, phenotypes, experimental data and text mining results. The BioXM platform allows all of the company’s external applications to access the data either directly or through application programming interfaces (APIs) and automates the updating of all integrated databases on a regular schedule.
“Boehringer Ingelheim has used the BioRS software for data integration for many years. Adding the BioXM software now lets them model their complete target discovery process in one easy-to-use, sustainable knowledge hub,” explained Dr. Kaj Albermann, who manages the Boehringer Ingelheim project at Biomax.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates and a total of around 50,000 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. www.boehringer-ingelheim.com
Boehringer Ingelheim is using the BioXM™ Knowledge Management Environment to build and maintain a target discovery knowledge platform that supports the company’s research on a global scale. The BioXM platform leverages Boehringer Ingelheim’s existing BioRS infrastructure to semantically integrate information from the company’s in-house systems and other proprietary and public data sources including pathways, compounds, sequences, genotypes, phenotypes, experimental data and text mining results. The BioXM platform allows all of the company’s external applications to access the data either directly or through application programming interfaces (APIs) and automates the updating of all integrated databases on a regular schedule.
“Boehringer Ingelheim has used the BioRS software for data integration for many years. Adding the BioXM software now lets them model their complete target discovery process in one easy-to-use, sustainable knowledge hub,” explained Dr. Kaj Albermann, who manages the Boehringer Ingelheim project at Biomax.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates and a total of around 50,000 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. www.boehringer-ingelheim.com
